Celularity Inc - Class A
Research Celularity Inc - Class A (CELU) on Bullrun: market cap USD 23.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCELU
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 23.19M
- Financial periodFY2025
- RevenueUSD 26.55M
- Revenue growth-51.0%
- Net income-USD 91.72M
- Free cash flow-USD 13.25M
- Gross margin24.4%
Valuation Snapshot
latest market cap is USD 23.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 26.55M | -USD 91.72M | -USD 13.25M | 24.4% | -3.59 | USD 6.18M | USD 40.90M | -USD 38.06M |
| FY2024 | USD 54.22M | -USD 57.89M | -USD 6.56M | 72.4% | -2.64 | USD 738.00K | USD 68.84M | USD 8.84M |
| FY2023 | USD 22.77M | -USD 196.30M | -USD 39.73M | 29.7% | -11.02 | USD 227.00K | USD 39.24M | USD 40.96M |
| FY2022 | USD 17.98M | USD 14.19M | -USD 143.11M | -9.4% | 0.95 | USD 13.97M | USD 37.60M | USD 198.90M |
| FY2021 | USD 21.34M | -USD 100.12M | -USD 116.30M | 54.8% | -1.49 | USD 37.24M | n/a | USD 99.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 23.19M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 32.01M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 46.90M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 47.83M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 187.07M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 636.46M | n/a | n/a | n/a |
About Celularity Inc - Class A
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Celularity Inc - Class A's market cap?
Celularity Inc - Class A's market capitalization is USD 23.19M.
What does Celularity Inc - Class A do?
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease.